Somatostatin Analogs (SSAs) for NETs: What to Expect
At a Glance
Somatostatin analogs (SSAs) like octreotide and lanreotide are common first-line treatments for neuroendocrine tumors (NETs). They work by binding to tumor cells to block excess hormone release, relieving carcinoid syndrome symptoms, and stopping the tumor from growing.
In this answer
4 sections
Somatostatin analogs (SSAs), such as octreotide and lanreotide, are often the first treatment prescribed for neuroendocrine tumors (NETs) [1]. They are synthetic, long-acting versions of a hormone called somatostatin that your body produces naturally. These medications work by attaching themselves to specific “landing pads” (called somatostatin receptors) found on the outside of NET cells [2]. Once attached, they perform two vital jobs: they block the tumor from releasing excess hormones to relieve daily symptoms [3], and they send signals inside the cell that can prevent the tumor from progressing [4].
How SSAs Control Your Symptoms
Many neuroendocrine tumors overproduce hormones like serotonin, leading to a cluster of symptoms known as carcinoid syndrome (severe diarrhea, skin flushing, and wheezing) [3].
When you receive an SSA injection, the medication binds directly to the tumor cells and blocks them from releasing these excess hormones into your bloodstream [5].
- Rapid Relief: For many patients, the medication begins reducing hormone levels quickly, with symptom relief noticeable within days to a few weeks, leading to a significant improvement in daily quality of life [6].
- Adjusting the Dose: If you experience breakthrough symptoms (symptoms that return before your next injection is due), your doctor might increase your dose, shorten the time between injections, or prescribe a short-acting, “rescue” version of the drug to take alongside your regular shot [7].
How SSAs Control Tumor Growth
In addition to controlling hormones, SSAs are tumoristatic, meaning they stabilize the tumor and stop the cells from multiplying [2]. While objective tumor shrinkage is rare, preventing the cancer from growing is a primary goal of this therapy.
- Interrupting Growth Signals: When the SSA binds to the receptor (specifically one called SSTR2), it blocks chemical pathways inside the cell that tell the tumor to grow [8].
- Proven Results: Major clinical trials (such as PROMID for octreotide and CLARINET for lanreotide) proved that these medications significantly improve progression-free survival—the amount of time you live with the disease without it getting worse [9]. Because of this, SSAs are widely used as a first-line systemic therapy to keep well-differentiated (slower-growing) tumors in check [10].
Octreotide vs. Lanreotide: Administration and Logistics
Octreotide and lanreotide are considered largely interchangeable when it comes to preventing tumor progression and controlling symptoms [11]. Both are typically given as a long-acting injection once a month [12].
- How They Are Given: Lanreotide is given as a deep injection just under the skin (subcutaneous), while long-acting octreotide is injected directly into a muscle (intramuscular) [12].
- Injection Logistics: Depending on the specific drug, your country’s regulations, and your insurance, injections may be administered at a cancer clinic, by a visiting home nurse, or, in some cases with lanreotide, safely by a trained spouse or family member [13].
- Practical Tip: Many patients find that allowing the medication syringe to reach room temperature for about 30 minutes before administration significantly reduces injection-site pain [14].
Important Side Effects to Monitor
While generally well-tolerated, SSAs do have some common and long-term side effects that require monitoring:
- Gallbladder Risks: Long-term use of SSAs slows down gallbladder emptying, creating a high risk for biliary sludge and gallstones [15]. Your care team may routinely monitor your gallbladder with ultrasounds, and you should report any new, severe upper-right abdominal pain.
- Digestive Issues: Gastrointestinal side effects, such as gas, floating stools, or changes in bowel habits, can occur because SSAs can reduce the enzymes your pancreas makes to digest fat [16]. If this happens, your doctor can prescribe pancreatic enzyme replacement therapy (digestive enzyme pills) to help you absorb your food.
- Blood Sugar Changes: SSAs can sometimes alter how your body processes glucose, leading to elevated blood sugar levels [17]. Clinical monitoring of your blood sugar (like A1c tests) will remain an important part of your ongoing care.
Common questions in this guide
How do somatostatin analogs (SSAs) help with carcinoid syndrome?
Do octreotide and lanreotide shrink neuroendocrine tumors?
What is the difference between octreotide and lanreotide injections?
What are the long-term side effects of taking SSAs?
What happens if my carcinoid syndrome symptoms return before my next injection?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my recent pathology report or DOTATATE PET scan confirm that my tumor has the specific somatostatin receptors (SSTR2) needed for this treatment to work?
- 2.If I start experiencing breakthrough symptoms of carcinoid syndrome before my next injection is due, what is our plan for adjusting the dose or frequency?
- 3.Are there options for me to receive these injections at home via a visiting nurse, or can a family member be trained to administer them?
- 4.How often will we do ultrasounds to monitor my gallbladder for stones, and what specific abdominal pain symptoms should I look out for?
- 5.If I develop greasy, floating stools or increased gas, at what point should we consider starting pancreatic digestive enzymes?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT, Kunz PL, Reidy-Lagunes DL
Clinical advances in hematology & oncology : H&O 2015; (13(5 Suppl 5)):1-18; quiz 1 p following 18.
PMID: 26430956 - 2
Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine.
Zhao J, Fu H, Yu J, et al.
Nature communications 2023; (14(1)):962 doi:10.1038/s41467-023-36673-z.
PMID: 36810324 - 3
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues.
Anthony LB, O'Dorisio TM
The oncologist 2021; (26(7)):e1171-e1178 doi:10.1002/onco.13847.
PMID: 34097784 - 4
177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E, Kabasakal L, Toklu T, et al.
Nuclear medicine communications 2018; (39(8)):789-796 doi:10.1097/MNM.0000000000000874.
PMID: 29912750 - 5
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K, Lamberts SW
Endocrine-related cancer 2016; (23(12)):R551-R566 doi:10.1530/ERC-16-0151.
PMID: 27697899 - 6
How I treat neuroendocrine tumours.
Kiesewetter B, Raderer M
ESMO open 2020; (5(4)) doi:10.1136/esmoopen-2020-000811.
PMID: 32817134 - 7
Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome.
Koumarianou A, Daskalakis K, Tsoli M, et al.
Journal of neuroendocrinology 2022; (34(7)):e13174 doi:10.1111/jne.13174.
PMID: 35794780 - 8
MicroRNAs and Treatment with Somatostatin Analogs in Gastro- Entero-Pancreatic Neuroendocrine Neoplasms: Challenges in Personalized Medicine.
Curt AM, Popa Ilie IR, Cainap C, et al.
Journal of gastrointestinal and liver diseases : JGLD 2020; (29(4)):647-659 doi:10.15403/jgld-2866.
PMID: 33331339 - 9
New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy.
Papaxoinis G, Syrigos K, Saif MW
Discovery medicine 2016; (21(117)):381-9.
PMID: 27355334 - 10
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M, Garcia-Carbonero R, Weber MM, et al.
The oncologist 2017; (22(3)):272-285 doi:10.1634/theoncologist.2016-0305.
PMID: 28220021 - 11
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Kiesewetter B, Pflüger FF, Melhorn P, et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025; (27(4)):1642-1652 doi:10.1007/s12094-024-03732-w.
PMID: 39316250 - 12
Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report.
Mohajeri-Tehrani MR, Ebrahimpur M, Nasseri-Moghaddam S, et al.
Journal of diabetes and metabolic disorders 2022; (21(2)):2009-2011 doi:10.1007/s40200-022-01067-3.
PMID: 36404816 - 13
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T, Kozlovacki G, Myrenfors P, Almquist M
Patient preference and adherence 2019; (13()):1799-1807 doi:10.2147/PPA.S213472.
PMID: 31695341 - 14
Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T, Safro M, Furlanetto DM, et al.
Journal of neuroendocrinology 2024; (36(1)):e13360 doi:10.1111/jne.13360.
PMID: 38088132 - 15
Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study.
Brighi N, Lamberti G, Maggio I, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2019; (51(5)):689-694 doi:10.1016/j.dld.2018.09.013.
PMID: 30314949 - 16
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
Wang L, Chen S, Wu M, Zhou L
Scientific reports 2025; (15(1)):18641 doi:10.1038/s41598-025-03850-7.
PMID: 40437077 - 17
Severe hyperglycemia following transition from octreotide to lanreotide in a patient with enterocutaneous fistula receiving parenteral nutrition.
Rosen AN, Balazh JR, Franck AJ
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2022; (37(3)):727-731 doi:10.1002/ncp.10757.
PMID: 34462966
This page explains somatostatin analog (SSA) therapy for educational purposes only. Always consult your oncologist or endocrinologist regarding your specific neuroendocrine tumor treatment plan and symptom management.
Get notified when new evidence is published on Tumor of endocrine glands.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.